XNAS
KRRO
Market cap104mUSD
Oct 08, Last price
10.58USD
1D
0.86%
1Q
-27.34%
IPO
-31.65%
Name
Frequency Therapeutics Inc
Chart & performance
P/E
—
P/S
16.47
EPS
—
Div yield, %
—
Shrs. gr., 5y
70.87%
Rev. gr., 5y
-29.61%
Revenues
6m
+181.46%
Net income
-117m
L+40.30%
CFO
-79m
L+30.77%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing treatments that unlock the body's inherent capacity for regeneration to restore impaired functions. Their "Progenitor Cell Activation" approach leverages small molecules to stimulate progenitor cells within the body, encouraging the formation of new, functional tissues. The company's flagship product candidate, FX-322, is currently in Phase IIa clinical trials, aiming to address the fundamental cause of sensorineural hearing loss. Beyond this, Frequency is also advancing therapies for various degenerative diseases, including multiple sclerosis, and ailments impacting muscles, the gastrointestinal system, skin, and bones. For the development and commercialization of FX-322, the company holds a license and collaboration agreement with Astellas Pharma Inc. Additionally, it maintains collaboration and licensing agreements with esteemed organizations such as Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Founded in 2014, Frequency Therapeutics, Inc. is headquartered in Lexington, Massachusetts.
Key people
Ram Aiyar
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director · since 2025
Vineet Agarwal
Chief Financial Officer · since 2025
Todd Chappell
Chief Operating Officer · since 2023
Stephanie Engels
Senior Vice President - People and Culture · since 2023
Venkat Krishnamurthy
Senior Vice President - Platform · since 2023
Gaozhong Zhu
Senior Vice President of Chemistry, Manufacturing and Controls · since 2025
Oliver Dolan
Principal Accounting Officer · since 2025
Loic Vincent
Chief Scientific Officer · since 2025
Jeffrey Cerio
Senior Vice President, General Counsel, Corporate Secretary · since 2024
Ali Behbahani
Independent Director · since 2023
Nessan Bermingham
Independent Chairman of the Board · since 2023
Jean-Francois Formela
Independent Director · since 2023
Katharine Knobil
Independent Director · since 2024
Rachel Meyers
Independent Director · since 2023
Timothy Pearson
Independent Director · since 2023
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||